Target intelligence / Profile preview

Signaling lymphocyte activation molecule family member 3 (SLAMF3)

Target
SLAMF3
Molecular classification
Receptor, Cell surface glycoprotein, Immunoglobulin superfamily, SLAM family
01

Overview

Signaling lymphocyte activation molecule family member 3 (SLAMF3), also known as CD229 or Ly9, is a type I transmembrane glycoprotein and a member of the SLAM family within the immunoglobulin superfamily (UniProt P06730). It is constitutively expressed on T and B lymphocytes and functions as a homophilic adhesion molecule that modulates lymphocyte activation, differentiation, and survival through interactions with cytoplasmic adapter proteins like SAP (SH2D1A). In clinical oncology, SLAMF3 is recognized as a highly specific marker for multiple myeloma cells, including myeloma stem cells, which has led to the development of CD229-targeted CAR-T cell therapies. Beyond malignancy, SLAMF3 plays a role in autoimmune diseases such as systemic lupus erythematosus, where its altered expression contributes to lymphocyte dysfunction. Therapeutic targeting of SLAMF3 aims to selectively eliminate cancer cells, though the shared expression on normal lymphocytes presents a challenge for maintaining long-term immune competence.

Other names
CD229Ly9T-lymphocyte surface antigen Ly-9Lymphocyte antigen 9SLAM family member 3
02

Mechanism of action

Targeted cell lysis via chimeric antigen receptor T-cell therapy and antibody-dependent cellular cytotoxicity (ADCC) to deplete SLAMF3-expressing malignant cells.

03

Biological functions

Immune responseCell adhesionSignal transductionT-cell activationB-cell developmentLymphocyte differentiation
04

Disease associations

CancerMultiple myelomaChronic lymphocytic leukemiaAutoimmune diseaseSystemic lupus erythematosus
05

Safety considerations

On-target off-tumor toxicity against healthy T and B cellsPotential for long-term T-cell aplasiaImmunosuppressionRisk of cytokine release syndrome (CRS) in CAR-T applications
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

SLAMF3 surface expressionCD229 expression on plasma cellsCD229 expression on myeloma stem cells

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Signaling lymphocyte activation molecule family member 3 (SLAMF3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Signaling lymphocyte activation molecule family member 3 (SLAMF3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call